工程化AAV载体通过整合TLR9拮抗序列规避先天免疫与炎症反应
该研究将拮抗TLR9激活的短DNA寡核苷酸整合入AAV载体基因组,以降低其免疫原性。工程化载体在小鼠和猪的肝脏、肌肉和视网膜中显著减少先天免疫与T细胞反应并增强基因表达。猪视网膜下高剂量AAV注射可致光感受器病理及微胶质和T细胞浸润,而对侧眼注射工程化载体则避免上述不良发现。但猕猴玻璃体内高剂量注射时,工程化载体仅延迟而未预防临床葡萄膜炎,提示除TLR9外其他免疫因素参与眼内炎症。
要点
- 将TLR9拮抗短DNA序列整合入AAV基因组可降低载体免疫原性并增强转基因表达。
- 在猪视网膜下注射模型中,工程化载体避免了高剂量AAV所致的光感受器病理和免疫细胞浸润。
- 猕猴玻璃体内注射时工程化载体仅延迟而不能预防葡萄膜炎,提示TLR9非唯一炎症通路。
核心结论
- 将特定免疫调节非编码序列与治疗性核酸连接可“ cloak”载体,在多种但非所有模型中避免不想要的免疫反应。
研究设计与样本
- 研究在临床相关的小鼠和猪模型以及猕猴模型中,比较了整合TLR9拮抗序列的工程化AAV载体与常规AAV载体的免疫原性和基因表达。
主要发现
- 工程化载体在肝脏、肌肉和视网膜中显著减少先天免疫和T细胞反应并增强基因表达。
- 猪视网膜下高剂量AAV注射导致光感受器病理及微胶质和T细胞浸润,而对侧眼注射工程化载体则避免这些不良发现。
- 猕猴玻璃体内高剂量注射工程化载体延迟但未预防临床葡萄膜炎。
临床怎么用
- 该“耦合免疫调节”策略可能拓宽AAV疗法及其他DNA基因转移方法的治疗窗口。
- 眼内注射途径的免疫风险需考虑TLR9以外的因素,尤其玻璃体内高剂量给药时。
局限性
- 猕猴玻璃体内注射模型中工程化载体仅延迟而未预防葡萄膜炎,提示其他免疫因素参与。
- 结果在多种但非所有模型中验证,尚未在所有临床相关场景中确认有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nucleic acids are used in many therapeutic modalities, including gene therapy, but their ability to trigger host immune responses in vivo can lead to decreased safety and efficacy. In the case of adeno-associated viral (AAV) vectors, studies have shown that the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition receptor that senses foreign DNA. Here, we engineered AAV vectors to be intrinsically less immunogenic by incorporating short DNA oligonucleotides that antagonize TLR9 activation directly into the vector genome. The engineered vectors elicited markedly reduced innate immune and T cell responses and enhanced gene expression in clinically relevant mouse and pig models across different tissues, including liver, muscle, and retina. Subretinal administration of higher-dose AAV in pigs resulted in photoreceptor pathology with microglia and T cell infiltration. These adverse findings were avoided in the contralateral eyes of the same animals that were injected with the engineered vectors. However, intravitreal injection of higher-dose AAV in macaques, a more immunogenic route of administration, showed that the engineered vector delayed but did not prevent clinical uveitis, suggesting that other immune factors in addition to TLR9 may contribute to intraocular inflammation in this model. Our results demonstrate that linking specific immunomodulatory noncoding sequences to much longer therapeutic nucleic acids can "cloak" the vector from inducing unwanted immune responses in multiple, but not all, models. This "coupled immunomodulation" strategy may widen the therapeutic window for AAV therapies as well as other DNA-based gene transfer methods.
引用
- Chan YK, Wang SK, Chu CJ, et al. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. 2021. PMID: 33568518. doi:10.1126/scitranslmed.abd3438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。